Amyloid β protein levels in cerebrospinal fluid are elevated in early‐onset Alzheimer's disease

Annals of Neurology

Volumn 36, Issue 6, 1994, Pages 903-911

  Nakamura, Tamiko ^a   Shoji, Mikio ^a   Harigaya, Yasuo ^a   Watanabe, Mitsunori ^a   Hosoda, Kenji ^b   Cheung, Tobun T ^c   Shaffer, Lillian M ^c   Golde, Todd E ^c   Younkin, Linda H ^c   Younkin, Steven G ^c   Hirai, Shunsaku ^a  

^a GUNMA UNIVERSITY   (Japan)

^b TEIJIN LTD   (Japan)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; ONSET AGE; PRIORITY JOURNAL;

ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; ALPHA 1-ANTICHYMOTRYPSIN; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; FEMALE; HUMAN; MALE; MIDDLE AGE; SUPPORT, NON-U.S. GOV'T;

EID: 0027994773     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.410360616     Document Type: Article

References (53)

1. Alzheimer's disease: initial report of purification and characterization of a novel cerebrovascular amyloid protein
2. Amyloid plaque core protein in Alzheimer disease and Down syndrome
3. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell‐surface receptor
4. Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein
5. Antisera to an amino‐terminal peptide detect the amyloid protein precursor of Alzheimer's disease and recognize senile plaques
6. The β‐amyloid protein precursor of Alzheimer disease has soluble derivatives found in human brain and cerebrospinal fluid
7. Soluble derivatives of the β amyloid protein precursor of Alzheimer's disease are labeled by antisera to the β amyloid protein
8. Cleavage of amyloid β peptide during constitutive processing of its precursor
9. Alzheimer's disease and control brain contain soluble derivatives of the amyloid protein precursor that end within the β amyloid protein region
10. The secreted form of the Alzheimer's amloid precursor protein with the Kunitz domain is protease nexin‐II
11. Secretion of β‐amyloid precursor protein cleaved at the amino terminus of the β‐amyloid peptide
12. Potentially amyloidogenic, carboxyl‐terminal derivatives of the amyloid protein precursor
13. Processing of the amyloid protein precursor to potentially amyloidogenic derivatives
14. Targeting of cell‐surface β‐amyloid precursor protein to lysosomes: alternative processing into amyloid‐bearing fragments
15. Production of the Alzheimer amyloid β protein by normal proteolytic processing
16. Amyloid β‐peptide is produced by cultured cells during normal metabolism
17. Isolation and quantification of soluble Alzheimer's β‐peptide from biological fluids
18. β‐Amyloid peptide and 3‐kDa fragment are derived by distinct cellular mechanisms
19. Generation of β‐amyloid in the secretory pathway in neuronal and non‐neuronal cells
20. Mass spectrometry of purified amyloid β protein in Alzheimer's disease
21. A pathogenic mutation for probale Alzheimer's disease in the APP gene at the N‐terminus of β‐amyloid
22. Mutation of the β‐amyloid precursor protein in familial Alzheimer's disease increases β‐protein production
23. Release of excess amyloid β protein from a mutant amyloid β protein precursor
24. Immunochemical identification of serine protease inhibitor α 1‐antichymotrypsin in the brain amyloid deposits of Alzheimer's disease
25. α 1‐antichymotrypsin as a possible biochemical marker for Alzheimer‐type dementia
26. Serological α 1‐antichymotrypsin in Down's syndrome and Alzheimer's disease
27. Alpha 1‐antichymotrypsin is present in diffuse plaques: a comparative study of β‐protein and α 1‐antichymotrypsin immunostaining in the Alzheimer brain
28. Clinical diagnosis of Alzheimer's disease: report of the NINCDS‐ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease
29. Mini‐Mental State” a practical method for grading the cognitive state of patients for the clinician
30. Functional staging of dementia of the Alzheimer type
31. The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution
32. Soluble derivatives of the β amyloid protein precursor in cerebrospinal fluid: alterations in normal aging and in Alzheimer's disease
33. Analysis and quantitation of the β‐amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients with a monoclonal anti‐body‐based immunoassay
34. Decreased levels of soluble amyloid β‐protein precursor in cerebrospinal fluid of live Alzheimer disease patients
35. Detection of amyloid beta protein precursor immunoreactivity in normal and Alzheimer's disease cerebrospinal fluid
36. Secretory pathway of β/A4 amyloid protein precursor in familial Alzheimer's disease with Val 717 to IIe mutation
37. Determination of amyloid β protein precursors harboring active form of proteinase inhibitor domains in cerebrospinal fluid of Alzheimer's disease patients by trypsin‐antibody sandwich ELISA
38. Amyloid β‐protein precursors with Kunitz‐type inhibitor domains and acetylcholinesterase in cerebrospinal fluid from patients with dementia of the Alzheimer type
39. Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis‐Dutch type share a decrease in cerebrospinal fluid levels of amyloid β‐protein precursor
40. Low cerebrospinal‐fluid concentrations of soluble amylolid β‐protein precursor in hereditary Alzheimer's disease
41. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implication for the pathogenesis of Alzheimer's disease
42. Apoliprotein E: binding to soluble Alzheimer's β‐amyloid
43. The cerebral‐fluid soluble form of Alzheimer's amyloid beta is complexed to SP‐40, 40 (apolipoprotein J), an inhibitor of the complement membrane‐attack complex
44. Blood–brain barrier transport of circulating Alzheimer's amyloid β
45. Diffuse type of senile plaques in the brains of Alzheimer‐type dementia
46. The pathological association between Down syndrome and Alzheimer disease
47. β‐Protein amyloid is widely distributed in the central nervous system of patients with Alzheimer's disease
48. Expression of β amyloid protein precursor mRNAs: recognition of a novel alternatively spliced form and quantitation in Alzheimer's disease using PCR
49. Differential expression of amyloid precursor protein mRNAs in cases of Alzheimer's disease and in aged nonhuman primates
50. Differential expression of β amyloid protein precursor (APP) and tau mRNA in the aged human brain: individual variability and correlation between APP‐751 and four‐repeat tau
51. Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease
52. Alzheimer β/A4 amyloid precursor protein in human brain: aging‐associated increases in holoprotein and in proteolytic fragment
53. Expression of APP in the early stage of brain damage